
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb has demonstrated a significant increase in its probability of success (PoS) for key drugs, such as milvexian and iber/mezi, leading to a robust increase in projected risk-adjusted sales, with estimates rising from $988 million to $1.2 billion for milvexian and from $1.3 billion to $3.6 billion for the combined sales of iber and mezi by 2033. The firm has also received positive guidance ahead of sell-side consensus, alleviating concerns about future performance, especially within its growth products and the anticipated strong sales growth of Eliquis. Additionally, trends in the market and strong physician feedback regarding CELMoDs have sparked investor interest, solidifying confidence in Bristol-Myers Squibb's growth trajectory and strategic direction in transformative therapies.
Bears say
Bristol-Myers Squibb's stock outlook is negatively impacted by a significant delay in the regulatory approval and launch date of a new product, which could detrimentally affect revenues and earnings. The company's forward EV/EBITDA multiple remains below the average of its peers at 11.2x, suggesting potential undervaluation in comparison to industry standards. Furthermore, the firm faces substantial risks in its clinical trials, including possible regulatory approval setbacks and evolving market conditions that could jeopardize the viability of new products or existing enhancements.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares